Dr. Svetlana Dambinova “NMDA receptor fragment & antibodies as biomarkers for MTBI "

Session 2, Friday, July 7, 2006

At the conclusion of this oral presentation, the participants will be able to:

1. Familiarize the role of NMDA receptors in cerebral ischemic events on early stage of mild traumatic brain injury (MTBI)
2. Evaluate and be aware of brain biomarkers' research translation from animal models to clinical studies
3. Explain the significance of NR2 peptide and NR2 antibodies in assessing acute and chronic cerebral ischemia followed MTBI
4. Describe the correlation of NR2 peptide and antibodies with clinical scores and neuroimaging data
5. Define and discuss diagnostic potential of new biomarkers to predict consequences of MTBI to healthcare benefit